NCT01912404: Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy |
|
|
| Terminated | 2 | 5 | US | IDN-6556, emricasan, PF-03491390, Placebo | Conatus Pharmaceuticals Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcoholic Hepatitis | 08/15 | 08/15 | | |